Scientists leverage machine learning and AI to guide vaccine development

From tackling homework challenges to drafting emails, people are discovering a vast array of applications for natural language processing tools like generative artificial intelligence (AI) engines.

Navigator secures $100m to develop antibody therapeutics

NAV-240 is undergoing Phase I development, focusing on complex autoimmune diseases. Credit: Panchenko Vladimir/Shutterstock. Navigator Medicines has secured $100m in a Series A financing round

August 28, 2024

Patient Claim Line outlines key signs of stroke and how to reduce risks

Every five minutes, someone in the UK will experience a stroke, with 1.3 million people in the country having survived a stroke. The condition can be both

October 26, 2024

Intellia’s gene editing therapy succeeds in Phase 2 genetic swelling condition study

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.